GLP-1 Receptor Agonist Clinical Evidence Guide
The Ozempic arm phenomenon is a recognized effect of GLP-1 receptor agonists causing localized subcutaneous fat loss. Understanding this helps clinicians counsel patients on expected body composition changes. This guide reviews clinical evidence relevant…
Semaglutide vs Tirzepatide: Clinical Evidence & FDA Data
This article reviews semaglutide tirzepatide clinical evidence focusing on comparative safety and efficacy. Both agents show significant weight loss and glycemic control benefits. Understanding their clinical evidence helps optimize patient care.
Tirzepatide Weight Loss: Clinical Outcomes and Evidence
Tirzepatide weight loss clinical outcomes demonstrate superior efficacy compared to other GLP-1 drugs. Clinical evidence supports its use for glycemic control and significant weight reduction. Understanding these outcomes helps clinicians optimize…
Policy Watch: DEA Scheduling Actions on Synthetic Drugs — June 18, 2026
This update covers DEA scheduling synthetic drugs 2026 with six key regulatory actions impacting clinical research and cannabis-related therapies. The DEA placed several novel synthetic substances into Schedule I, affecting legal status and research…
Schedules of Controlled Substances: Placement of MDMB-4en-PINACA in Schedule I
The DEA synthetic cannabinoids schedule I placement 2026 includes MDMB-4en-PINACA, a potent synthetic cannabinoid with high abuse potential. This scheduling reflects significant clinical concerns about its adverse effects and lack of medical use.…
Schedules of Controlled Substances: Rescheduling of FDA Approved Cannabis Products from Schedule I to III
The rescheduling FDA approved cannabis products implications are significant for clinical practice. This change reduces regulatory barriers and improves patient access to cannabis-derived medications. It allows clinicians to prescribe these medications…
Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I
The DEA synthetic cannabinoids schedule I placement 2026 update highlights the inclusion of four novel cannabinoids into Schedule I. This reflects their high abuse potential and lack of accepted medical use. Clinicians should be vigilant for synthetic…
Challenges in Regulating Synthetic Cannabinoids: Schedule I Placement
The synthetic cannabinoid regulation challenges are highlighted by the DEA's placement of CUMYL-PEGACLONE in Schedule I. This classification reflects high abuse potential and no accepted medical use. Clinicians must understand these regulatory challenges…
Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
The Drug Enforcement Administration has enacted the temporary placement of 2-fluorodeschloroketamine in Schedule I of the Controlled Substances Act. This scheduling restricts the availability of this synthetic ketamine analog due to its high abuse…
Updates on Diphenidine Scheduling in Controlled Substances
The diphenidine scheduling update reflects its placement in Schedule I due to high abuse potential and no accepted medical use. This synthetic dissociative drug poses challenges for clinicians in identifying abuse. Awareness of diphenidine scheduling…